QNCX
EquityQuince Therapeutics, Inc.
Health Care · Biotechnology
$0.13
+0.13 (+0.00%)
Open
N/A
Day Range
$0.10 - $0.13
52W Range
$0.10 - $4.55
Volume
27M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.61 | N/A | - | +0.00% |
| AHCO | AdaptHealth Corp. | $9.15 | N/A | - | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.66 | N/A | - | +0.00% |
| AGEN | Agenus Inc. | $3.33 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $24.56 | N/A | - | +0.00% |
| ABT | Abbott Laboratories | $116.35 | N/A | 2.06% | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | N/A | - | +0.00% |
| A | Agilent Technologies, Inc. | $121.38 | N/A | 0.82% | +0.00% |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
www.quincetx.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for QNCX
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for QNCX.